Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes;Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2

Revista Clinica Espanola

Volumn 211, Issue 3, 2011, Pages 147-155

  Menendez Torre E ^a   Lafita Tejedor, J ^a   Artola Menendez S ^a   Millan Nunez Cortes J ^b   Alonso Garcia A ^b   Puig Domingo, M ^b   Garcia Solans J R ^b   Alvarez Guisasola F ^b   Garcia Alegria J ^b   Mediavilla Bravo, J ^b   Miranda Fernandez Santos C ^b   Romero Gonzalez R ^b  

^a En Representacion Del Grupo de Trabajo de Consensos y Guias Clinicas de la Soc Espanola de Diabetes   (Spain)

^b Sociedad Española de Arteriosclerosis ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN;

EID: 79953119107     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2010.11.006     Document Type: Article

References (81)

1. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, and R. Sherwin Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care. 32 2009 193 203
2. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the prevention and management of diabetes in Canada Can J Diabetes. 32 Suppl 1 2008 S1 S201
3. Algoritmo de tratamiento de la diabetes tipo 2. Guía de práctica clínica sobre diabetes tipo 2. Ministerio de Sanidad y Consumo, 2008. Disponible en: http://www9.euskadi.net/sanidad/osteba/datos/e-06- 06-Diabetes-tipo-2.pdf
4. GEDAPS 2009. Algoritmo de tratamiento de la diabetes tipo 2. Disponible en: http://www. redgedaps.org/.
5. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians; 2009. Disponible en: http://www.nice. org.uk/nicemedia/live/12165/44318/44318.pdf
6. AACE/ACE Consensus Statement Statement by an American Association of Clinical Endocrinologist/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract. 15 2009 540 559
7. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med. 353 2005 2643 2653
8. R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A.W. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med. 359 2008 1577 1589
9. The ADVANCE collaborative group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med. 358 2008 2560 2572
10. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, P.D. Reaven for the VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med. 360 2009 129 139
11. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med. 358 2008 2545 2559
12. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality and in type 2 diabetes N Engl J Med. 358 2008 580 591 (Pubitemid 351214285)
13. A.E. Kitabchi, G.E. Umpierrez, J.M. Miles, and J.N. Fisher Hyperglycemic crises in adult patients with diabetes Diabetes Care. 32 2009 1335 1343
14. Look AHEAD Research Group Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial Diabetes Care. 30 2007 1374 1383
15. R. DeFronzo, and A. Goodman Eficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group N Engl J Med. 333 1995 541 549
16. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 352 1998 854 865
17. A.J. Krentz, R.E. Ferner, and C.J. Bailey Comparative tolerability profiles of oral antidiabetic agents Drug Saf. 11 1994 223 241 (Pubitemid 24308246)
18. A. Holstein, A. Plaschke, and E.-H. Egberts Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide Diabetes Metab Res Rev. 17 2001 467 473 (Pubitemid 34030749)
19. A.S. Gangji, T. Cukierman, H.C. Gerstein, C.H. Goldsmith, and C.M. Clase A systematic review and meta-analysis of hipoglicemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin Diabetes Care. 30 2007 389 394 (Pubitemid 46198354)
20. A. Holstein, A. Plaschke, and E.H. Egberts Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide Diabetes Metab Res Rev. 17 2001 467 473 (Pubitemid 34030749)
21. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones ADOPT Study Group Glycemic durability of rosiglitazone, metformin or glyburide monotherapy N Engl J Med. 355 2006 2427 2443 (Pubitemid 44903747)
22. G. Belcher, C. Lambert, G. Edwards, R. Urquhart, and D.R. Matthews Safety and tolerability of pioglitazone, metformin and gliclazide in the treatment of type 2 diabetes Diab Res Clin Pract. 70 2005 53 62 (Pubitemid 41207648)
23. I.W. Campbell, D.G. Menzies, J. Chalmers, A.M. McBain, and I.R. Brown One year comparative trial of metformin and glipizide in type 2 diabetes mellitus Diabet Metab. 20 1994 394 400
24. R. Scott, L. Wu, M. Sánchez, and P. Stein Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract. 61 2007 171 180
25. P. Aschner, M.S. Kipnes, J.K. Lunceford, M. Sánchez, C. Mickel, and D.E. Williams-Herman Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care. 29 2006 2632 2637 (Pubitemid 44912190)
26. V. Mohan, W. Yang, H.Y. Son, L. Xu, L. Noble, and R.B. Langdon Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India and Korea Diabetes Res Clin Pract. 83 2009 106 116
27. B. Göke, K. Hershon, D. Kerr, A. Calle Pascual, A. Schweizer, and J. Foley Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with Metformin Horm Metab Res. 40 2008 892 895
28. J. Rosenstock, C. Aguilar-Salinas, E. Klein, S. Nepal, J. List, R. Chen CV181-011 Study Investigators Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes Curr Med Res Opin. 25 2009 2401 2411
29. O.E. Johansen, and K.I. Birkeland Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review Am J Cardiovasc Drugs. 7 2007 319 335 (Pubitemid 47624536)
30. J. Rosenstock, D.R. Hassman, R.D. Madder, S.A. Brazinsky, J. Farrell, and N. Khutoryansky Repaglinide versus nateglinide monotherapy: a randomized, multicenter study Diabetes Care. 27 2004 1265 1270 (Pubitemid 38679968)
31. C. Black, P. Donnelly, L. McIntyre, P.L. Royle, J.P. Shepherd, and S. Thomas Meglitinide analogues for type 2 diabetes mellitus Cochrane Database Syst Rev. 2 2007 CD004654
32. J.F. Blicklé Meglitinide analogues: a review of clinical data focused on recent trials Diabetes Metab. 32 2006 113 120
33. J. Waugh, G.M. Keating, G.L. Plosker, S. Easthope, and D.M. Robinson Pioglitazone: a review of its use in type 2 diabetes mellitus Drugs. 66 2006 85 109 (Pubitemid 43144963)
34. P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, and M. Hanefeld Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet. 373 2009 2125 2135
35. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, and I.K. Moules Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomized controlled trial Lancet. 366 2005 1279 1289 (Pubitemid 41416583)
36. D.J. Graham, R. Ouellet-Hellstrom, T.E. Macurdy, F. Ali, C. Sholley, and C. Worrall Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone JAMA. 304 2010 411 418
37. H.E. Lebovitz, and M.A. Banerji Insulin resistance and its treatment by thiazolidinediones Recent Prog Horm Res. 56 2001 265 294
38. R. Belfort, S.A. Harrison, and K. Brown A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med. 355 2006 2297 2307 (Pubitemid 44837778)
39. F.A. Van de Laar, P.L. Lucassen, R.P. Akkermans, E.H. Van de Lisdonk, and W.J. De Grauw Alphaglucosidase inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev. 2 2005 CD003639
40. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso STOP-NIDDM Trial Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet. 359 2002 2072 2077 (Pubitemid 34680970)
41. E.A. Ryan, S. Imes, and C. Wallace Short-term intensive insulin therapy in newly diagnosed type 2 diabetes Diabetes Care. 27 2004 1028 1032 (Pubitemid 38579760)
42. Z.T. Bloomgarden Exploring treatment strategies for type 2 diabetes Diabetes Care. 30 2007 2737 2745 (Pubitemid 47547829)
43. I. Lingvay, J.L. Legendre, P.F. Kaloyanova, S. Zhang, B. Adams-Huet, and P. Raskin Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care. 32 2009 1789 1795
44. A.J. Garber, J. Larsen, S.H. Schneider, B.A. Piper, and D. Henry Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes Diabetes Obes Metab. 4 2002 201 208 (Pubitemid 34567677)
45. L.S. Hermann, B. Scherstén, P.O. Bitzén, T. Kjellström, F. Lindgärde, and A. Melander Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations A double-blind controlled study. Diabetes Care. 17 1994 1100 1109 (Pubitemid 24307443)
46. UK Prospective Diabetes Stud-54y (UKPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
47. J. Olsson, G. Lindberg, M. Gottsater, K. Lindwall, A. Sjostrand, and A. Tisell Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population based observational study Diabetologia. 43 2000 558 560 (Pubitemid 30322072)
48. E. Mannucci, M. Monami, G. Masotti, and N. Marchionni All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides Diabetes Metab Res Rev. 20 2004 44 47 (Pubitemid 38196247)
49. E.Z. Fisman, A. Tenenbaum, V. Boyko, M. Benderly, Y. Adler, and A. Friedensohn Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up Clin Cardiol. 24 2001 151 158 (Pubitemid 32108625)
50. K.H. Kahler, M. Rajan, G. Rhoads, M.M. Safford, K. Demissie, and S.E. Lu Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration Diabetes Care. 30 2007 1689 1693 (Pubitemid 47036337)
51. J.A. Johnson, S.R. Majumdar, S.H. Simpson, and E.L. Toth Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes Diabetes Care. 25 2002 2244 2248 (Pubitemid 41071035)
52. R. Moses, R. Slobodniuk, S. Boyages, S. Colagiuri, W. Kidson, and J. Carter Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care. 22 1999 119 124 (Pubitemid 29028307)
53. P. Raskin, L. Klaff, J. McGill, S.A. South, P. Hollander, and N. Khutoryansky Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin Diabetes Care. 26 2003 2063 2068 (Pubitemid 41184253)
54. P. Raskin Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes Diabetes Obes Metab. 10 2008 1167 1177
55. B. Ahrén Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin -diabetes control and potential adverse events Best Pract Res Clin Endocrinol Metab. 23 2009 487 498
56. E. Bosi, R.P. Camisasca, C. Collober, E. Rochotte, and A.J. Garber Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin Diabetes Care. 30 2007 890 895 (Pubitemid 46556583)
57. M.A. Nauck, G. Meininger, D. Sheng, L. Terranella, P.P. Stein Sitagliptin Study 024 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab. 9 2007 194 205 (Pubitemid 46206563)
58. E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahrén, and S. Byiers Fifty-two-week ef.cacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes Obes Metab. 11 2009 157 166
59. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care. 28 2005 1092 1100 (Pubitemid 40616618)
60. M. Monami, N. Marchionni, and E. Mannucci Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials Eur J Endocrinol. 160 2009 909 917
61. L.F. Van Gaal, S.W. Gutkin, and M.A. Nauck Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol. 158 2008 773 784 (Pubitemid 351837365)
62. D.C. Klonoff, J.B. Buse, L.L. Nielsen, X. Guan, C.L. Bowlus, and J.H. Holcombe Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin. 24 2008 275 286 (Pubitemid 351160260)
63. B. Zinman, B.J. Hoogwerf, S. Durán García, D.R. Milton, J.M. Giaconia, and D.D. Kim The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial Ann Int Med. 146 2007 477 485 (Pubitemid 351650556)
64. E. Montanya, and G. Sesti A review of ef.cacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus Clin Ther. 31 2009 2472 2488
65. J. Rosenstock, J. Rood, A. Cobitz, C. Huang, and A. Garber Improvement in glycaemic control with rosiglitazone/metformin.xed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control Diabetes Obes Metab. 8 2006 643 649 (Pubitemid 44515561)
66. G. Bolli, F. Dotta, L. Colin, B. Minic, and M. Goodman Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin Diabetes Obes Metab. 11 2009 589 595
67. R. Rajagopalan, S. Iyer, and M. Khan Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials Curr Med Res Opin. 21 2005 163 172 (Pubitemid 40327518)
68. A. Ceriello, D. Johns, M. Widel, D.J. Eckland, K.J. Gilmore, and M.H. Tan Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes Diabetes Care. 28 2005 266 272 (Pubitemid 40170924)
69. H. Yki-Jarvinen, L. Ryysy, K. Nikkila, T. Tulokas, R. Vanamo, and M. Heikkila Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus Ann Int Med. 130 1999 389 396 (Pubitemid 29111220)
70. M.C. Riddle, J. Rosenstock, J. Gerich Insulin Glargine 4002 Study Investigators The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care. 26 2003 3080 3086 (Pubitemid 37339502)
71. S.G. Swinnen, M.P. Dain, R. Aronson, M. Davies, H.C. Gerstein, and A.F. Pfeiffer A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs Diabetes Care. 33 2010 1176 1178
72. J.L. Chiasson, L. Naditch Miglitol Canadian University Investigator Group The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes Diabetes Care. 24 2001 989 994 (Pubitemid 33716364)
73. J.A. Kiayias, E.D. Vlachou, E. Theodosopoulou, and E. Lakka-Papadodima Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients Diabetes Care. 25 2002 1251 1252
74. G.E. Dailey, M.A. Noor, J.S. Park, S. Bruce, and F.T. Fiedorek Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial Am J Med. 116 2004 223 229 (Pubitemid 38224229)
75. R. Roy, M. Navar, G. Palomeno, and M.B. Davidson Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent Diabetes Care. 27 2004 1741 1742
76. G. Charpentier, and S. Halimi Earlier triple therapy with pioglitazone in patients with type 2 diabetes Diabetes Obes Metab. 11 2009 844 854
77. A.J. Scheen, M.H. Tan, D.J. Betteridge, K. Birkeland, O. Schmitz, B. Charbonnel PROactive investigators Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17) Diabet Med. 26 2009 1033 1039
78. G. Papa, V. Fedele, M.R. Rizzo, M. Fioravanti, C. Leotta, and S.B. Solerte Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: a randomized, open-label, two-period, cross-over trial Diabetes Care. 29 2006 1918 1920 (Pubitemid 44156653)
79. K. Hermansen, M. Kipnes, E. Luo, D. Fanurik, H. Khatami, and P. Stein Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Sitagliptin Study 035 Group Diabetes Obes Metab. 9 2007 733 745 (Pubitemid 47261855)
80. M.T. Tran, M.D. Navar, and M.B. Davidson Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes Diabetes Care. 29 2006 1395 1396 (Pubitemid 44125944)
81. R.R. Holman, A.J. Farmer, M.J. Davies, J.C. Levy, J.L. Darbyshire, J.F. Keenan, S.K. Paul 4-T Study Group Three-year efficacy of complex insulin regimens in type 2 diabetes N Engl J Med. 361 2009 1736 1747